{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:58:57Z","timestamp":1773863937395,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008091","name":"University of Rochester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007890","name":"University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008114","name":"University of Nebraska-Lincoln","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omton.2025.201089","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T01:42:54Z","timestamp":1763084574000},"page":"201089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus"],"prefix":"10.1016","volume":"33","author":[{"given":"Cassandra","family":"Catacalos-Goad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dakota W.","family":"Goad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly C.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quinton","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isha M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Abdul","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-3840","authenticated-orcid":false,"given":"Valery Z.","family":"Grdzelishvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.201089_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2023.6.JNS23243","article-title":"Oncolytic viral therapy: a review and promising future directions","volume":"140","author":"Reddy","year":"2024","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.omton.2025.201089_bib2","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1099\/vir.0.046672-0","article-title":"Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer","volume":"93","author":"Hastie","year":"2012","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.omton.2025.201089_bib3","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/jgv.0.000980","article-title":"Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update","volume":"98","author":"Felt","year":"2017","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.omton.2025.201089_bib4","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2025.201089_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051171","article-title":"Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions","volume":"13","author":"Holbrook","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.201089_bib6","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1128\/JVI.05640-11","article-title":"Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma","volume":"86","author":"Murphy","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201089_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.virol.2012.11.014","article-title":"Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling","volume":"436","author":"Moerdyk-Schauwecker","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.omton.2025.201089_bib8","doi-asserted-by":"crossref","first-page":"61601","DOI":"10.18632\/oncotarget.11202","article-title":"Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus","volume":"7","author":"Hastie","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2025.201089_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.omto.2021.11.019","article-title":"Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus","volume":"24","author":"Goad","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201089_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01005-23","article-title":"Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells","volume":"97","author":"Goad","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201089_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jss.2013.10.032","article-title":"Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma","volume":"187","author":"Blackham","year":"2014","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.omton.2025.201089_bib12","article-title":"Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma","volume":"33","author":"Watters","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2025.201089_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00461-17","article-title":"Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus","volume":"91","author":"Felt","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201089_bib14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.virol.2015.08.003","article-title":"Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1","volume":"485","author":"Cataldi","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.omton.2025.201089_bib15","article-title":"Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer","volume":"32","author":"Geoffroy","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2025.201089_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41417-018-0074-6","article-title":"JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models","volume":"26","author":"Patel","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2025.201089_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.21","article-title":"Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy","volume":"3","author":"Dold","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201089_bib18","doi-asserted-by":"crossref","first-page":"33165","DOI":"10.18632\/oncotarget.5320","article-title":"Vesicular stomatitis virus expressing interferon-beta is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Patel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2025.201089_bib19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/cgt.2013.55","article-title":"Overcoming cancer cell resistance to VSV oncolysis with JAK1\/2 inhibitors","volume":"20","author":"Escobar-Zarate","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2025.201089_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: A systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omton.2025.201089_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.24572","article-title":"Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients","volume":"92","author":"Polverelli","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omton.2025.201089_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","article-title":"Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis","volume":"28","author":"Caocci","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.201089_bib23","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.21873\/anticanres.17315","article-title":"Fostamatinib Inhibits the Proliferation of Ovarian Cancer Cells Through Apoptosis Induction","volume":"44","author":"Lee","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2025.201089_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2025.201089_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.cgt.7700794","article-title":"Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice","volume":"12","author":"Ebert","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2025.201089_bib26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/JVI.02040-09","article-title":"Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells","volume":"84","author":"Wollmann","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201089_bib27","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1093\/cid\/ciab732","article-title":"Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial","volume":"75","author":"Strich","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.omton.2025.201089_bib28","article-title":"Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury","volume":"1","author":"Tabassum","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omton.2025.201089_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.02284-24","article-title":"METTL3 depletion blocks vesicular stomatitis virus replication in pancreatic cancer cells through the establishment of an intrinsic antiviral state","volume":"99","author":"Catacalos-Goad","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201089_bib30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/jso.23316","article-title":"The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer","volume":"107","author":"Curry","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.omton.2025.201089_bib31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clim.2007.03.543","article-title":"Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor","volume":"124","author":"Pine","year":"2007","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omton.2025.201089_bib32","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s40262-022-01135-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406","volume":"61","author":"Matsukane","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omton.2025.201089_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.175","article-title":"In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib","volume":"3","author":"Rolf","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.omton.2025.201089_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/art.42321","article-title":"Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"75","author":"Prendecki","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.omton.2025.201089_bib35","article-title":"Drug repurposing of fostamatinib against cancer via potential cytotoxicity and immune checkpoint regulation","volume":"16","author":"Hu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201089_bib36","article-title":"KDM6A Deficiency Induces Myeloid Bias and Promotes CMML-Like Disease Through JAK\/STAT3 Activation by Repressing SOCS3","volume":"12","author":"Chen","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omton.2025.201089_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104257","article-title":"Targeting spleen tyrosine kinase (SYK): structure, mechanisms and drug discovery","volume":"30","author":"Zhang","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omton.2025.201089_bib38","article-title":"Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes Immune Escape by Upregulating SYK\/Nuclear Factor-kappaB Signaling in Diffuse Large B-cell Lymphoma","volume":"105","author":"Jiang","year":"2025","journal-title":"Lab. Invest."},{"key":"10.1016\/j.omton.2025.201089_bib39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.molcel.2024.11.026","article-title":"MYO1F positions cGAS on the plasma membrane to ensure full and functional signaling","volume":"85","author":"Wang","year":"2025","journal-title":"Mol. Cell"},{"key":"10.1016\/j.omton.2025.201089_bib40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ni921","article-title":"IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway","volume":"4","author":"Fitzgerald","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2025.201089_bib41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nature04374","article-title":"Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response","volume":"439","author":"Oganesyan","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.201089_bib42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12916-024-03314-1","article-title":"TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro","volume":"22","author":"Duan","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.omton.2025.201089_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01885-18","article-title":"Cell Cycle Arrest in G(2)\/M Phase Enhances Replication of Interferon-Sensitive Cytoplasmic RNA Viruses via Inhibition of Antiviral Gene Expression","volume":"93","author":"Bressy","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201089_bib44","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.201089_bib45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41421-021-00271-4","article-title":"Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response","volume":"7","author":"Wang","year":"2021","journal-title":"Cell Discov."},{"key":"10.1016\/j.omton.2025.201089_bib46","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1186\/s12885-021-08911-4","article-title":"Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma","volume":"21","author":"Kiryu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2025.201089_bib47","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-17-0162","article-title":"Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers","volume":"23","author":"Knudsen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201089_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1323198","article-title":"Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma","volume":"15","author":"Joseph","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201089_bib49","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1128\/JVI.00211-06","article-title":"Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells","volume":"80","author":"Das","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201089_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF02796382","article-title":"Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites","volume":"18","author":"Chen","year":"1982","journal-title":"In Vitro"},{"key":"10.1016\/j.omton.2025.201089_bib51","first-page":"54","article-title":"Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9","volume":"78","author":"Iwamura","year":"1987","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.omton.2025.201089_bib52","first-page":"601","article-title":"Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies","volume":"42","author":"Metzgar","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201089_bib53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/jnci\/56.4.843","article-title":"Epithelial cell cultures from normal and cancerous human tissues","volume":"56","author":"Owens","year":"1976","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:26:18Z","timestamp":1773836778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925001584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950329925001584"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.201089","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.201089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201089"}}